 Biotech stocks rebounded in the holiday-shortened week ending July 2 as investors reacted to pending clinical trial readouts and the news flow surrounding COVID-19 vaccine and treatment development. Australian biopharma Alterity Therapeutics Ltd NASDAQ: ATHE was among the biggest gainers of the week after the company said it received FDA guidance for the Phase 2 study for its Parkinsonian disorder drug.Inovio Pharmaceuticals Inc NASDAQ: INO and Pfizer Inc. NYSE: PFE BioNTech SE - ADR NASDAQ: BNTX were among the companies that issued updates on their coronavirus vaccine programs. The week also saw FDA issuing guidance on the approval of COVID-19 vaccines, with the agency suggesting a vaccine needs to demonstrate at least 50 efficacy in a placebo-controlled trial.The following are key catalysts for the unfolding week:Conferences SVB Leerink Biopharma Private Company Connect: July 7-9 The Society for Pediatric Dermatology, or SPD, 45th Annual Meeting virtual: July 10-12PDUFA Dates BioSpecifics Technologies Corp. NASDAQ: BSTC and its marketing partner Endo International PLC NASDAQ: ENDP await the FDAs decision on the BLA for collagenase clostridium histolyticum in treating cellulite MondayThe FDA is also due to rule on Eagle Pharmaceuticals Incs NASDAQ: EGRX NDA for Ryanodex, which is being evaluated as a potential treatment option for exertional heat stroke. WednesdayRelated Link: Global Blood Analyst Projects More Than 60 Upside On Receding Sickle Cell Drug Concerns Clinical Readouts Obseva SA NASDAQ: OBSV will release Phase 3 PRIMROSE 1, six-month primary endpoint results, and PRIMROSE 2 12-month data for Linzagolix in uterine fibroids. Monday ahead of the market openUpdate: ObSeva reported positive results for the late-stage PRIMROSE 1 and PRIMROSE 2 studies that evaluated its linzagolix in uterine fibroids. The stock was reacting negatively, with SVB Leerink analyst Ami Fadia attributing the weakness to underwhelming PRIMOSE 1 data relative to PRIMEROSE 2 data.Abeona Therapeutics Inc NASDAQ: ABEO is due to present two abstracts related to its clinical program for recessive dystrophic epidermolysis bullosa, or RDEB, at the SPD annual meeting. The company will present detailed data on long-term pain relief following durable healing of wounds in RDEB patients treated with EB-101 in a Phase 12 study.IPO Quiet Period Expiry Lantern Pharma Inc. NASDAQ: LTRN Burning Rock Biotech Ltd NASDAQ: BNR Generation Bio Co NASDAQ: GBIO Vaxcyte Inc NASDAQ: PCVX Avidity Biosciences Inc NASDAQ: RNA Royalty Pharma plc NASDAQ: RPRXOther Events Chembio Diagnostics Inc NASDAQ: CEMI is scheduled to announce its current plans for COVID-19 product development and regulatory approvals and its preliminary estimates of revenue results for the quarter ended June 30, 2020. Monday after the closeIncidentally, FDA emergency use authorization for Chembios SARS-CoV-2 antibody test was revoked last month.See also: Attention Biotech Investors: Mark Your Calendar For These July PDUFA Dates See more from Benzinga The Daily Biotech Pulse: Novartis Settles Lawsuit For 8M, Sarepta In-Licenses Gene Therapy Pre-Treatment, Unity Biotech Outlines Second-Half Catalysts The Daily Biotech Pulse: T2 Biosystems Launches COVID-19 Test, Akero Aces Midstage NASH Study, Aravive Added to Russell IndexesC 2020 Benzinga.com. Benzinga does not provide investment advice. All rights reserved. 